Reported Saturday, Delcath Systems Posts $20.5M Q3 Revenue, $0.8M Net Income And 87% Gross Margin; Sees 2025 Revenue Outlook Of $83M–$85M With 150% Treatment Volume Growth Forecast

Author: Benzinga Newsdesk | October 20, 2025 02:52am

Preliminary Third Quarter Financial Results (unaudited)

• Total CHEMOSAT and HEPZATO KIT revenue of approximately $20.5 million
  • HEPZATO KIT revenue of $19.2 million
  • CHEMOSAT revenue of $1.3 million
• Gross margins expected to be 87%

Net income of $0.8 million

• Positive adjusted EBITDA of $5.3 million

Positive operating cashflow of approximately $4.8 million

As of September 30, 2025, the Company had approximately $88.9 million of cash, cash equivalents and short-term investments and no debt.
 

2025 Full Year Financial Guidance

• Total CHEMOSAT and HEPZATO KIT revenue of $83 million to $85 million, reflecting an approximate 150% increase in treatment volume over 2024
• Quarterly gross margins between 85% to 87%
• Positive adjusted EBITDA and operating cashflow in each quarter of 2025

Posted In: DCTH